Drug Pricing Scandal: Pharma’s Loss Is Medtech’s Gain
The scandal swirling round drug pricing is pushing investors to medical device stocks in lieu of pharmaceutical and biotech plays.
Edwards Lifesciences (NYSE:EW), Boston Scientific (NYSE:BSX) and Becton Dickinson & Co. (NYSE:BDX) shares have outperformed the broad healthcare sector, and especially pharmaceutical and biotech shares, since U.S. presidential candidate Hillary Clinton tweeted she planned to address specialty drug “price gouging” 2 months ago.
Edwards Lifesciences (NYSE:EW), Boston Scientific (NYSE:BSX) and Becton Dickinson & Co. (NYSE:BDX) shares have outperformed the broad healthcare sector, and especially pharmaceutical and biotech shares, since U.S. presidential candidate Hillary Clinton tweeted she planned to address specialty drug “price gouging” 2 months ago.